YY1-C/EBPα-miR34a regulatory circuitry is involved in renal cell carcinoma progression

Weng,Wenhao; Wang,Minli; Xie,Suhong; Long,Yin; Li,Feng; Sun,Fenyong; Yu,Yongchun; Li,Zhi

doi:10.3892/or.2014.3005

YY1-C/EBPα-miR34a regulatory circuitry is involved in renal cell carcinoma progression

Authors:
- Wenhao Weng
- Minli Wang
- Suhong Xie
- Yin Long
- Feng Li
- Fenyong Sun
- Yongchun Yu
- Zhi Li
View Affiliations

Affiliations: Department of Laboratory Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Laboratory Medicine, Shanghai Putuo District Central Hospital, Shanghai 200013, P.R. China, Department of Laboratory Medicine, Shanghai Yangpu District Central Hospital, Shanghai 200090, P.R. China
Published online on: January 30, 2014 https://doi.org/10.3892/or.2014.3005
Pages: 1921-1927

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is a common urological malignancy. It remains unclear, however, whether Yin Yang 1 (YY1) plays a functional role in the development of human RCC. In the present study, we demonstrated that levels of YY1 were significantly increased in primary RCC tissues when compared to these levels in the matched healthy tissues. YY1 knockdown inhibited cell growth, migration and invasion of RCC cells. Additionally, we highlighted a positive feedback-loop pathway resulting in YY1 upregulation. We observed that overexpression of YY1 caused repression of C/EBPα and the inhibition of C/EBPα led to the suppression of miR-34a. Since YY1 is a direct target of miR-34a, the low level of miR-34a increased the expression of YY1, promoting the aggressiveness of RCC cells. Furthermore, this feedforward mechanism was found in RCC tissues. We observed that miR-34a was downregulated in the pools of cancer tissues when compared to that of the normal tissues. The expression of miR-34a displayed an inverse correlation with YY1, but a positive correlation with C/EBPα. In conclusion, our study highlights the importance of a novel regulatory circuitry for YY1 activation in maintaining the aggressive phenotypes of RCC.

View Figures

View References

1	Liou LS, Shi T, Duan ZH, et al: Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urol. 4:92004. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
3	Chow WH, Devesa SS, Warren JL and Fraumeni JF Jr: Rising incidence of renal cell cancer in the United States. JAMA. 281:1628–1631. 1999. View Article : Google Scholar : PubMed/NCBI
4	Amato RJ: Chemotherapy for renal cell carcinoma. Semin Oncol. 27:177–186. 2000.PubMed/NCBI
5	Bukowski RM: Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 80:1198–1220. 1997. View Article : Google Scholar : PubMed/NCBI
6	Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
7	Castellano G, Torrisi E, Ligresti G, et al: The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle. 8:1367–1372. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zaravinos A and Spandidos DA: Yin yang 1 expression in human tumors. Cell Cycle. 9:512–522. 2010. View Article : Google Scholar
9	Riggs KJ, Saleque S, Wong KK, et al: Yin-yang 1 activates the c-myc promoter. Mol Cell Biol. 13:7487–7495. 1993.PubMed/NCBI
10	Lee JS, Galvin KM, See RH, et al: Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300. Genes Dev. 9:1188–1198. 1995. View Article : Google Scholar : PubMed/NCBI
11	Gronroos E, Terentiev AA, Punga T and Ericsson J: YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci USA. 101:12165–12170. 2004. View Article : Google Scholar : PubMed/NCBI
12	Wu S, Murai S, Kataoka K and Miyagishi M: Cooperative regulation of p73 promoter by Yin Yang 1 and E2F1. Nucleic Acids Symp Ser. 51:347–348. 2007. View Article : Google Scholar : PubMed/NCBI
13	Brodersen P and Voinnet O: Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol. 10:141–148. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kim VN: MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 6:376–385. 2005. View Article : Google Scholar : PubMed/NCBI
15	Fujita Y, Kojima K, Hamada N, et al: Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 377:114–119. 2008. View Article : Google Scholar : PubMed/NCBI
16	Li Y, Guessous F, Zhang Y, et al: MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 69:7569–7576. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wei JS, Song YK, Durinck S, et al: The MYCN oncogene is a direct target of miR-34a. Oncogene. 27:5204–5213. 2008. View Article : Google Scholar : PubMed/NCBI
18	Welch C, Chen Y and Stallings RL: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007. View Article : Google Scholar : PubMed/NCBI
19	Li N, Fu H, Tie Y, et al: miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 275:44–53. 2009. View Article : Google Scholar : PubMed/NCBI
20	Tazawa H, Tsuchiya N, Izumiya M and Nakagama H: Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA. 104:15472–15477. 2007. View Article : Google Scholar : PubMed/NCBI
21	Chang TC, Wentzel EA, Kent OA, et al: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 26:745–752. 2007. View Article : Google Scholar : PubMed/NCBI
22	Liu C, Kelnar K, Liu B, et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
23	Akao Y, Noguchi S, Iio A, Kojima K, Takagi T and Naoe T: Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 300:197–204. 2011. View Article : Google Scholar : PubMed/NCBI
24	Huang GL, Zhang XH, Guo GL, et al: Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep. 21:673–679. 2009.PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
26	Zhang S, Jiang T, Feng L, et al: Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha. J Mol Med. 90:1069–1077. 2012. View Article : Google Scholar
27	Pulikkan JA, Peramangalam PS, Dengler V, et al: C/EBPalpha regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood. 116:5638–5649. 2010. View Article : Google Scholar : PubMed/NCBI
28	Shi Y, Seto E, Chang LS and Shenk T: Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell. 67:377–388. 1991. View Article : Google Scholar : PubMed/NCBI
29	Galvin KM and Shi Y: Multiple mechanisms of transcriptional repression by YY1. Mol Cell Biol. 17:3723–3732. 1997.PubMed/NCBI
30	Tong ZT, Cai MY, Wang XG, et al: EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 31:583–594. 2012.PubMed/NCBI
31	de Nigris F, Crudele V, Giovane A, et al: CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc Natl Acad Sci USA. 107:14484–14489. 2010.PubMed/NCBI
32	Lee MH, Lahusen T, Wang RH, et al: Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation. Oncogene. 31:116–127. 2012. View Article : Google Scholar : PubMed/NCBI
33	Austen M, Cerni C, Luscher-Firzlaff JM and Luscher B: YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc. Oncogene. 17:511–520. 1998. View Article : Google Scholar : PubMed/NCBI
34	Wang CC, Tsai MF, Dai TH, et al: Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1. Cancer Res. 67:4816–4826. 2007. View Article : Google Scholar : PubMed/NCBI
35	Samarakoon R and Higgins PJ: Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Haemost. 100:976–983. 2008.PubMed/NCBI
36	Girard N, Tremblay M, Humbert M, et al: RARalpha-PLZF oncogene inhibits C/EBPalpha function in myeloid cells. Proc Natl Acad Sci USA. 110:13522–13527. 2013. View Article : Google Scholar : PubMed/NCBI
37	Schuster MB and Porse BT: C/EBPalpha: a tumour suppressor in multiple tissues? Biochim Biophys Acta. 1766:88–103. 2006.PubMed/NCBI
38	Lopez RG, Garcia-Silva S, Moore SJ, et al: C/EBPalpha and beta couple interfollicular keratinocyte proliferation arrest to commitment and terminal differentiation. Nat Cell Biol. 11:1181–1190. 2009. View Article : Google Scholar : PubMed/NCBI
39	Ramji DP and Foka P: CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 365:561–575. 2002.PubMed/NCBI
40	Pabst T and Mueller BU: Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res. 15:5303–5307. 2009. View Article : Google Scholar : PubMed/NCBI
41	Perrotti D, Cesi V, Trotta R, et al: BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet. 30:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
42	Sato A, Yamada N, Ogawa Y and Ikegami M: CCAAT/enhancer-binding protein-alpha suppresses lung tumor development in mice through the p38alpha MAP kinase pathway. PloS One. 8:e570132013. View Article : Google Scholar : PubMed/NCBI